West Pharmaceutical Services, Inc. (WST)
Is WST Stock Undervalued At $200?
West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales of $749 million and adjusted earnings per share of $1.82, compared to $740 million and $1.73, respectively.
West Pharmaceutical Services, Inc. (WST) Q4 2024 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank David Windley - Jefferies Jacob Johnson - Stephens Inc. Operator Thank you for standing by and welcome to West Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance
On Thursday, West Pharmaceutical Services, Inc. WST reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72.
West Pharmaceutical forecasts 2025 results below expectations, shares drop
West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong dollar and as the medical equipment maker's clients reduce inventory levels, sending its shares down 18% premarket.
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.83 per share a year ago.
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
LH vs. WST: Which Stock Is the Better Value Option?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.
West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Thomas DeBourcy - Nephron Research Operator Good day and thank you for standing by. Welcome to the Q3 2024 West Pharmaceutical Services Earnings Conference Call.
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.
